IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Sophie V. Vandebroek Sells 344 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded down $0.01 on Friday, reaching $421.75. 338,607 shares of the company traded hands, compared to its average volume of 505,750. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a 50 day moving average of $451.91 and a 200 day moving average of $478.11. The firm has a market capitalization of $34.53 billion, a PE ratio of 40.67, a PEG ratio of 3.68 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period in the prior year, the firm earned $2.53 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analyst Ratings Changes

IDXX has been the subject of several recent research reports. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Piper Sandler reissued a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. decreased their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $552.38.

Institutional Trading of IDEXX Laboratories

A number of institutional investors have recently modified their holdings of the business. American Trust purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $757,000. Franklin Resources Inc. lifted its stake in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after buying an additional 34,305 shares in the last quarter. Tidal Investments LLC lifted its stake in shares of IDEXX Laboratories by 7.6% during the 3rd quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock valued at $3,188,000 after buying an additional 444 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in shares of IDEXX Laboratories by 20.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 3,288 shares of the company’s stock valued at $1,661,000 after buying an additional 558 shares in the last quarter. Finally, Toronto Dominion Bank lifted its stake in shares of IDEXX Laboratories by 1.9% during the 3rd quarter. Toronto Dominion Bank now owns 42,283 shares of the company’s stock valued at $21,362,000 after buying an additional 808 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.